Safety evaluation of the food enzyme thermolysin from the non‐genetically modified Anoxybacillus caldiproteolyticus strain DP‐Fzj32 Authors: EFSA Panel on Food Enzymes (FEZ), Holger Zorn, José Manuel Barat Baviera, Claudia Bolognesi, Francesco Catania, Gabriele Gadermaier, Ralf Greiner, Baltasar Mayo, Alicja Mortensen, Yrjö Henrik Roos, Marize L M Solano, Henk Van Loveren, Laurence Vernis, Cristina Andreoli, Andrea Terron, Natália Kovalkovičová, Magdalena Andryszkiewicz, Daniele Cavanna, Ana Gomes, Yi Liu Published: 2026 ABSTRACT AbstractThe food enzyme thermolysin (EC 3.4.24.27) is produced with the non‐genetically modified Anoxybacillus caldiproteolyticus strain DP‐Fzj32 by Danisco US Inc. The food enzyme was considered free from viable cells of the production organism. It is intended to be used in three food manufacturing processes. Dietary exposure was estimated to be up to 0.874 mg food enzyme–total organic solids (TOS)/kg body weight (bw) per day in European populations. Genotoxicity tests did not indicate a safety concern. The systemic toxicity was assessed by means of a repeated dose 90‐day oral toxicity study in rats. The Panel identified a no observed adverse effect level of 108 mg TOS/kg bw per day, the highest dose tested. The calculated margins of exposure were 232 (infants), 314 (toddlers), 124 (children), 1200 (adolescents), 2250 (adults) and 2348 (the elderly). A search for the homology of the amino acid sequence of the thermolysin to known allergens was made and no match was found. The Panel considered that a risk of allergic reactions upon dietary exposure cannot be excluded, but that the likelihood is low. Based on the data provided, the Panel concluded that this food enzyme does not give rise to safety concerns, under the intended conditions of use, for infants, toddlers, adolescents, adults and the elderly. However, the margin of exposure is insufficient to exclude safety concerns for children.Keywords: Anoxybacillus caldiproteolyticus, EC 3.4.24.27, EFSA‐Q‐2015‐00682, food enzyme, Geobacillus caldoproteolyticus, non‐genetically modified microorganism, thermoase, thermolysin INTRODUCTION Article 3 of the Regulation (EC) No 1332/2008 1 provides definition for ‘food enzyme’ and ‘food enzyme preparation’. ‘Food enzyme’ means a product obtained from plants, animals or microorganisms or products thereof including a product obtained by a fermentation process using microorganisms: (i) containing one or more enzymes capable of catalysing a specific biochemical reaction; and (ii) added to food for a technological purpose at any stage of the manufacturing, processing, preparation, treatment, packaging, transport or storage of foods. ‘Food enzyme preparation’ means a formulation consisting of one or more food enzymes in which substances such as food additives and/or other food ingredients are incorporated to facilitate their storage, sale, standardisation, dilution or dissolution. Before January 2009, food enzymes other than those used as food additives were not regulated or were regulated as processing aids under the legislation of the Member States. On 20 January 2009, Regulation (EC) No 1332/20081 on food enzymes came into force. This Regulation applies to enzymes that are added to food to perform a technological function in the manufacture, processing, preparation, treatment, packaging, transport or storage of such food, including enzymes used as processing aids. Regulation (EC) No 1331/2008 2 established the European Union (EU) procedures for the safety assessment and the authorisation procedure of food additives, food enzymes and food flavourings. The use of a food enzyme shall be authorised only if it is demonstrated that: it does not pose a safety concern to the health of the consumer at the level of use proposed; it does not pose a safety concern to the health of the consumer at the level of use proposed; there is a reasonable technological need; there is a reasonable technological need; its use does not mislead the consumer. its use does not mislead the consumer. All food enzymes currently on the EU market and intended to remain on that market, as well as all new food enzymes, shall be subjected to a safety evaluation by the European Food Safety Authority (EFSA) and approval via an EU Community list. Background and Terms of Reference as provided by the requestor Background as provided by the European Commission Only food enzymes included in the European Union (EU) Community list may be placed on the market as such and used in foods, in accordance with the specifications and conditions of use provided for in Article 7(2) of Regulation (EC) No 1332/20081 on food enzymes. Five applications have been introduced by the companies ‘Danisco US Inc.’ for the authorisation of the food enzymes Alpha‐amylase from a genetically modified strain of Trichoderma reesei (DP‐Nzb48) and Thermolysin from Geobacillus caldoproteolyticus strain (DP‐Fzj32), and ‘Amano Enzyme Inc.’ for the authorisation of the food enzymes AMP deaminase from Streptomyces murinus (strain AE‐DNTS), Beta‐galactosidase from Aspergillus oryzae (strain AE‐LA) and Dextranase from Chaetomium erraticum (strain AE‐DX). Following the requirements of Article 12.1 of Regulation (EC) No 234/20113 implementing Regulation (EC) No 1331/2008,2 the Commission has verified that the five applications fall within the scope of the food enzyme Regulation and contains all the elements required under Chapter II of that Regulation. Terms of Reference The European Commission requests the European Food Safety Authority to carry out the safety assessments on the food enzymes Alpha‐amylase from a genetically modified strain of Trichoderma reesei (DP‐Nzb48), Thermolysin from Geobacillus caldoproteolyticus strain (DP‐Fzj32), AMP deaminase from Streptomyces murinus (strain AE‐DNTS), Beta‐galactosidase from Aspergillus oryzae (strain AE‐LA) and Dextranase from Chaetomium erraticum (strain AE‐DX) in accordance with Article 17.3 of Regulation (EC) No 1332/20081 on food enzymes. Interpretation of the Terms of Reference The present scientific opinion addresses the European Commission's request to carry out the safety assessment of the food enzyme thermolysin from the non‐genetically modified Geobacillus caldoproteolyticus strain (DP‐Fzj32). Recent data identified the production microorganism as Anoxybacillus caldiproteolyticus (Section 3.1). Therefore, this name will be used in this opinion instead of G. caldoproteolyticus. DATA AND METHODOLOGIES Data The applicant has submitted a dossier in support of the application for authorisation of the food enzyme thermolysin from G. caldoproteolyticus strain (DP‐Fzj32). The dossier was updated on 8 February 2016. Additional information, requested from the applicant during the assessment phase on 4 January 2016, 27 March 2023 and 18 March 2026, was received on 8 February 2016, 27 January 2026 and 13 April 2026, respectively (see ‘Documentation provided to EFSA’). Following the request for additional data sent by EFSA on 27 March 2023, the applicant requested a clarification teleconference on 18 September 2023, after which the applicant provided additional data on 27 January 2026. Methodologies The assessment was conducted in line with the principles described in the EFSA ‘Guidance on transparency in the scientific aspects of risk assessment’ (EFSA, 2009) and following the relevant guidance documents of the EFSA Scientific Committee. The ‘Guidance on the submission of a dossier on food enzymes for safety evaluation’ (EFSA CEF Panel, 2009) as well as the ‘Statement on characterisation of microorganisms used for the production of food enzymes’ (EFSA CEP Panel, 2019) have been followed for the evaluation of the application. Additional information was requested in accordance with the updated ‘Scientific Guidance for the submission of dossiers on food enzymes’ (EFSA CEP Panel, 2021) and the guidance on the ‘Food manufacturing processes and technical data used in the exposure assessment of food enzymes’ (EFSA CEP Panel, 2023). ASSESSMENT IUBMB nomenclatureThermolysinSystematic name–Synonyms Bacillus thermoproteolyticus neutral proteinase; thermoaseIUBMB NoEC 3.4.24.27CAS No37246‐64‐3EINECS No253‐424‐5 Thermolysins catalyse the hydrolysis the peptide bonds of proteins with broad specificity, but preferentially between leucine and phenylalanine, releasing peptides and amino acids. The food enzyme under assessment is intended to be used in three food manufacturing processes as defined in the EFSA guidance (EFSA CEP Panel, 2023): (1) processing of dairy products for the production of modified milk proteins; (2) processing of meat and fish products for the production of protein hydrolysates from meat and fish proteins; (3) processing of plant‐ and fungal‐derived products for the production of protein hydrolysates from plants and fungi. Source of the food enzyme The thermolysin is produced with the non‐genetically modified bacterium A. caldiproteolyticus (formerly Geobacillus caldiproteolyticus) strain DP‐Fzj32 (■■■■■), 3 which is deposited at the Westerdijk Fungal Biodiversity Institute culture collection (CBS, the Netherlands) with deposition number ■■■■■. 4 The production strain was identified as A. caldiproteolyticus by ■■■■■ 5 The production strain A. caldiproteolyticus DP‐Fzj32 is a natural isolate from the ■■■■■ without modification. 6 The whole genome sequence (WGS) of the production strain was interrogated for the presence of antimicrobial resistance (AMR) genes using two regularly updated databases with thresholds of 80% identity and 70% coverage. No AMR genes of concern were identified. 7 No information on WGS‐based analysis of virulence/toxin genes was provided, a limitation discussed in Section 3.3.3. Production of the food enzyme The food enzyme is manufactured according to the Food Hygiene Regulation (EC) No 852/2004, 8 with food safety procedures based on Hazard Analysis and Critical Control Points and in accordance with Good Manufacturing Practice. 9 The production strain is grown as a pure culture using a typical industrial medium in a batch or fed‐batch fermentation system with conventional process controls in place. After completion of the fermentation, the solid biomass is removed from the fermentation broth by filtration. The filtrate containing the enzyme is then further purified and concentrated, including an ultrafiltration step in which enzyme protein is retained, while most of the low molecular mass material passes the membrane and is discarded. 10 The applicant provided information on the identity of the substances used to control the fermentation and in the subsequent downstream processing of the food enzyme. 11 The Panel considered that sufficient information has been provided on the manufacturing process and the quality assurance system implemented by the applicant to exclude issues of concern. Characteristics of the food enzyme Properties of the food enzyme The thermolysin is composed of ■■■■■ amino acids 12 and the molecular mass of the mature protein, calculated from the amino acid sequence, is ■■■■■ kDa. 13 The food enzyme was analysed by sodium dodecyl sulfate‐polyacrylamide gel electrophoresis. 14 A consistent protein pattern was observed across all batches. The gel showed a major protein band corresponding to an apparent molecular mass of about ■■■■■ kDa in all batches, consistent with the expected molecular mass of the enzyme. No other enzyme activities were reported. 15 The determination of thermolysin activity is based on the hydrolysis of the casein (reaction conditions: pH 6.5, 37°C, 60 min). The release of soluble peptides not precipitated by trichloroacetic acid is measured spectrophotometrically at 280 nm. The enzyme activity is expressed in protease units (XS)/g. One XS is the amount of enzyme that produces 1 μg of tyrosine equivalent per min under the assay conditions. 16 The food enzyme has a temperature optimum around 65°C (pH 7.5, 15 min) and a pH optimum around 5.2 (65°C, 15 min). Thermostability was tested by pre‐incubation of the food enzyme for 10 min at different temperatures (pH 7.5). The enzyme activity decreased above 60°C, showing no residual activity at 90°C. 17 Chemical parameters Data were provided for three batches of the food enzyme intended for commercialisation and one batch produced for the toxicological tests (Table 1). 18 The mean total organic solids (TOS) of the three batches intended for commercialisation was 8.2% and the mean enzyme activity/TOS ratio was 5.3 XS/mg TOS. TABLE 1Composition of the food enzyme preparation.ParametersUnitBatches1234 a Thermolysin activity XS/g b 419441432214 Protein %4.34.54.32.15 Ash %2.11.82.08.7 Water %89.689.890.157.6■■■■■ (excipient) %–––23.4 Total organic solids (TOS) c %8.38.47.910.3 Thermolysin activity/TOS ratio XS/mg TOS5.05.35.52.0 a Batch used for the toxicological studies. b Unit: XS/g (see Section 3.3.1). c TOS calculated as 100% – % water – % ash – % excipient. Composition of the food enzyme preparation. Batch used for the toxicological studies. Unit: XS/g (see Section 3.3.1). TOS calculated as 100% – % water – % ash – % excipient. Purity 19 The lead content in all the batches was below 5 mg/kg 20 which complies with the specification for lead as laid down in the general specifications for enzymes used in food processing (FAO/WHO, 2006). In addition, arsenic, cadmium and mercury concentrations in the batch used for toxicological testing were below the limits of detection (LoD) of the employed methods. 21 , 22 The food enzyme complies with the microbiological criteria for total coliforms, Escherichia coli and Salmonella, as laid down in the general specifications for enzymes used in food processing (FAO/WHO, 2006). 23 No antimicrobial activity was detected in any of the tested batches. 24 No data were provided on the presence of toxicity genes (Section 3.1). The possible presence of toxic compounds in the food enzyme is addressed by the toxicological tests (Section 3.4). The Panel considered that the information provided on the purity of the food enzyme is sufficient. Viable cells of the production strain The absence of viable cells of the production strain in the food enzyme was demonstrated in three independent batches analysed in triplicate. ■■■■■ ■■■■■ ■■■■■ No colonies were detected. A positive control was included. 26 Toxicological data 27 A battery of toxicological tests including a bacterial reverse mutation test (Ames test), an in vitro mammalian chromosomal aberration test and a repeated dose 90‐day oral toxicity study in rats has been provided. The batch 4 (Table 1) used in these tests has a lower enzyme activity/TOS ratio; hence, it is less pure as compared to the batches intended for commercialisation and therefore is considered suitable as a test item. Genotoxicity Bacterial reverse mutation test A bacterial reverse mutation test (Ames test) was performed according to the Organisation for Economic Co‐operation and Development (OECD) Test Guideline 471 (OECD, 1997a) and following Good Laboratory Practice (GLP). 28 Four strains of Salmonella Typhimurium (TA98, TA100, TA1535 and TA1537) and E. coli WP2uvrA pKM101 were used with or without metabolic activation (S9‐mix), applying the ‘treat and plate’ assay. The preliminary test and two main experiments were carried out in triplicate. The preliminary experiment was carried out using five concentrations of the food enzyme of 110–5375 μg TOS/plate. Toxic effects, evident as a reduction in relative survival, occurred in TA1535, TA1537 and TA98 strains at ≥ 110 μg TOS/plate and in TA100 and E. coli WP2uvrA pKM101 strains at ≥ 1075 μg TOS/plate without S9‐mix. No cytotoxicity was observed at any concentration of the test substance with S9‐mix. Based on these results, the first experiment was carried out using five concentrations of the food enzyme of 10–170 μg TOS/plate in TA1537 strain, of 20–335 μg TOS/plate in TA1535 and TA98 strains, of 85–1345 μg TOS/plate in TA100 strain, of 335–5375 μg TOS/plate in E. coli WP2uvrA pKM101 without S9‐mix and of 335–5375 μg TOS/plate in all strains with S9‐mix. Toxic effects, evident as a significant reduction in relative survival and/or the background bacterial lawn, occurred in TA1535 strain at 335 μg TOS/plate, in TA1537 strain at 85 and 170 μg TOS/plate, in TA98 strain at 170 and 335 μg TOS/plate, in TA100 strain at 670 μg TOS/plate and in E. coli WP2uvrA pKM101 at 5375 μg TOS/plate without S9‐mix and in TA1535 strain at ≥ 1345 μg TOS/plate, in TA98 strain at ≥ 2690 μg TOS/plate and in E. coli WP2uvrA pKM101 at 5375 μg TOS/plate with S9‐mix. Upon treatment with the food enzyme, an increase in the revertant colony numbers was observed at 170 μg TOS/plate in TA100 strain without S9‐mix and at concentrations of 1345, 2690 and 5375 μg TOS/plate in TA1537 strain with S9‐mix. The second experiment was carried out using five concentrations of the food enzyme of 20–335 μg TOS/plate in TA1535 and TA98 strains, of 10–170 μg TOS/plate in TA1537 strain, of 170–2690 μg TOS/plate in TA100 and E. coli WP2uvrA pKM101 strains without S9‐mix and of 335–5375 μg TOS/plate in all strains with S9‐mix. Toxic effects, evident as a significant reduction in relative survival and/or the background bacterial lawn, occurred in TA1535 strain at 335 μg TOS/plate, in TA1537 strain at 85 and 170 μg TOS/plate, in TA98 strain at ≥ 85 μg TOS/plate without S9‐mix and in all strains at 2690 and 5375 μg TOS/plate with S9‐mix. Upon treatment with the food enzyme, an increase in revertant colony numbers was observed at 335 μg TOS/plate in TA1535 strain without S9‐mix and at concentrations of 670 and 2690 μg TOS/plate in TA98 strain with S9‐mix. The Panel noted that in main experiments no concentration‐response relationship was observed, the increases were not reproducible and the values were within the historical control range (except the concentration of 2690 μg TOS/plate in TA98 strain with S9‐mix) and therefore the changes were not considered to be of biological relevance. The Panel concluded that the food enzyme did not induce gene mutations under the test conditions applied in this study. In vitro mammalian chromosomal aberration test The in vitro mammalian chromosomal aberration test was carried out according to the OECD Test Guideline 473 (OECD, 1997b) and following GLP. 29 Two separate experiments were performed with duplicate cultures of human peripheral whole blood lymphocytes. The cell cultures were treated with the food enzyme either with or without metabolic activation (S9‐mix). In the first experiment, cells were exposed to the food enzyme and scored for chromosomal aberrations at concentrations 269, 540 and 1075 μg TOS/mL in a short‐term treatment (3‐h exposure and 17‐h recovery period) either with or without S9‐mix. In the second experiment, cells were exposed to the food enzyme and scored for chromosomal aberrations at concentrations of 269, 540 and 1075 μg TOS/mL in a short‐term treatment (3‐h exposure and 17‐h recovery period) with S9‐mix and in a long‐term treatment (20‐h exposure without recovery period) without S9‐mix. No cytotoxicity was seen in the short‐term treatment (with or without S9‐mix). In the long‐term treatment, cytotoxicity of 60% (mitotic index) was observed at 1075 μg TOS/mL. The frequency of structural and numerical aberrations was not statistically significantly different to the negative controls at any concentration tested. The Panel concluded that the food enzyme did not induce an increase in the frequency of structural and numerical aberrations under the test conditions applied in this study. Repeated dose 90‐day oral toxicity study in rodents The repeated dose 90‐day oral toxicity study was performed under GLP and according to the OECD Test Guideline 408 (OECD, 1998). 30 Groups of 10 male and 10 female Sprague–Dawley (Crl:CD(SD)) IGS BR rats received the food enzyme by gavage in doses of 27, 54 and 108 mg TOS/kg bw per day. 31 Controls received the vehicle (4.6% sorbitol and 1.6% NaCl aqueous solution in purified water). One mid‐dose female was found dead on day 43 of administration, two high‐dose females were found dead on day 41 and 48 of administration. The Panel considered the deaths as due to mis‐dosing because no relevant clinical signs were observed prior to deaths, and the microscopic examination revealed pulmonary oedema. The body weight change was statistically significantly decreased on days 29–36 of administration in mid‐dose males (−15%) and increased on days 64–71 in high‐dose males (+56%) and on days 78–85 in low‐, mid‐ and high‐dose males (+500%, +450%, +600%). The Panel considered the changes as not toxicologically relevant, as they were only recorded sporadically, only observed in one sex, there was no dose–response relationship (on days 29–36 and 78–85), the changes were without a statistically significant effect on the final body weight and the final body weight gain. Haematological investigations revealed a statistically significant decrease in eosinophils (Eos) in low‐, mid‐ and high‐dose males (−35%, −40% and −30%), a decrease in lymphocytes (Lymph) in high‐dose males (−23%), a decrease in haemoglobin concentration in low‐ and mid‐dose males (−3% both), a decrease in mean corpuscular haemoglobin concentration (MCHC) in mid‐dose males (−2%) and a decrease in prothrombin time (PT) in low‐dose females (−6%). The Panel considered the changes as not toxicologically relevant, as they were only observed in one sex (all parameters), there was no dose–response relationship (all parameters except for Lymph), the changes were small (MCHC, PT), there were no statistically significant changes in other relevant parameters (for Eos and Lymph in the total white blood cell count; for MCHC in total count of erythrocytes; for PT in activated partial thromboplastin time and fibrinogen) and the changes were within the historical control values (all parameters). Clinical chemistry investigations revealed a statistically significant decrease in inorganic phosphorus concentration in high‐dose males (−9%), an increase in potassium concentration (K) in low‐dose males (+7%), a decrease in total proteins (TP; −4%, −3%) and in albumin (Alb; −8%, −5%) in low‐ and mid‐dose males, and an increase in urea concentration in high‐dose females (+21%). The Panel considered the changes as not toxicologically relevant, as they were only observed in one sex (all parameters), there was no dose–response relationship (K, TP, Alb), there were no histopathological changes in liver and kidneys and the changes were within the historical control values (all parameters). The urinalysis revealed a statistically significant decrease in specific gravity in low‐ and mid‐dose males (−1% both) and an increase in volume of urine collected in mid‐dose males (+80%). The Panel considered the changes as not toxicologically relevant, as they were only observed in one sex (both parameters), there was no dose–response relationship (both parameters), there were no histopathological changes in kidneys and the changes were within the historical control values (both parameters). Statistically significant changes detected in organ weights were a decrease in the absolute brain weight in mid‐dose females (−6%). The Panel considered the change as not toxicologically relevant, as it was only observed in one sex, there was no dose–response relationship, the change was small and there were no histopathological changes in brain and the change was within the historical control values. No toxicologically relevant or other statistically significant differences from controls were reported. The Panel identified a no observed adverse effect level (NOAEL) of 108 mg TOS/kg bw per day, the highest dose tested. Allergenicity 32 The allergenicity assessment considered only the food enzyme and not additives, carriers or other excipients that may be used in the final formulation. The potential allergenicity of the thermolysin produced with the A. caldiproteolyticus strain DP‐Fzj32 was assessed by comparing its amino acid sequence with those of known allergens as described in the EFSA GMO Scientific Opinion (EFSA GMO Panel, 2010). Using higher than 35% identity in a sliding window of 80 amino acids as the criterion, no match was found in the AllergenOnline database. 33 No reports on oral and respiratory sensitisation or elicitation reactions of the food enzyme under assessment have been published. 34 No allergic reactions upon dietary exposure to any thermolysin have been reported in the literature. The Panel considered that the results of the sequence homology search and the available literature do not indicate a risk of allergic reactions upon dietary exposure to the thermolysin under assessment. ■■■■■, a product from ■■■■■ that may cause allergies or intolerances (listed in the Regulation (EU) No 1169/2011 35 ) is used as a raw material. In addition, ■■■■■, known sources of allergens, are present in the culture medium. During the fermentation process, these products will be mostly degraded and utilised by the production strain. The Panel considered that residual amounts of allergenic proteins due to the raw material could be present in the food enzyme. Taking into account the level of dietary exposure (see Section 3.5), this would result in minute amounts in the final foods, from which allergic reactions are usually not expected. In conclusion, the Panel considered that under the intended conditions of use, a risk of allergic reactions upon dietary exposure to this food enzyme cannot be excluded, but that the likelihood is low. Dietary exposure The food enzyme is intended to be used in three food manufacturing processes at the recommended use levels summarised in Table 2. TABLE 2Intended uses and recommended use levels of the food enzyme as provided by the applicant. 36 Food manufacturing processRaw material (RM)Recommended use level (mg TOS/kg RM) a Processing of dairy products Production of modified milk proteins Milk proteins16.3–163 Processing of meat and fish products Production of protein hydrolysates from meat and fish proteins Meat and fish proteins33–163 Processing of plant‐ and fungal‐derived products Production of protein hydrolysates from plants and fungi Plant and fungal proteins 37 16.3–163 Abbreviation: TOS, total organic solids. a The numbers in bold represent the maximum recommended use levels, which were used for calculation. Intended uses and recommended use levels of the food enzyme as provided by the applicant. 36 Production of modified milk proteins Production of modified milk proteins Production of protein hydrolysates from meat and fish proteins Production of protein hydrolysates from meat and fish proteins Production of protein hydrolysates from plants and fungi Production of protein hydrolysates from plants and fungi Abbreviation: TOS, total organic solids. The numbers in bold represent the maximum recommended use levels, which were used for calculation. In the production of modified milk proteins, the food enzyme is added to improve solubility and taste. 38 The food enzyme–TOS remain in the resulting modified milk proteins. In the production of protein hydrolysates, the food enzyme is added to a variety of protein‐rich materials from animal (e.g. meat, fish), plant or fungal sources. 39 The food enzyme–TOS remain in these protein hydrolysates. Based on data provided on thermostability (see Section 3.3.1) and the downstream processing within the respective food manufacturing processes, the Panel considered that the food enzyme is inactivated in the food manufacturing processes listed in Table 2. Dietary exposure estimation Chronic exposure to the food enzyme–TOS was calculated using the FEIM webtool 40 by combining the maximum recommended use level with individual consumption data (EFSA CEP Panel, 2021). The estimation involved selection of relevant food categories and application of technical conversion factors (EFSA CEP Panel, 2023). Table 3 provides an overview of the derived exposure estimates across all surveys. Detailed mean and 95th percentile exposure to the food enzyme–TOS per age class, country and survey, as well as contribution from each FoodEx category to the total dietary exposure are reported in Appendix A – Tables 1 and 2. For the present assessment, food consumption data were available from 51 dietary surveys (covering infants, toddlers, children, adolescents, adults and the elderly), carried out in 27 European countries (Appendix B). The highest dietary exposure was estimated to be 0.874 mg TOS/kg bw per day in children at the 95th percentile. TABLE 3Summary of the estimated dietary exposure to the food enzyme–TOS in six population groups.Population groupEstimated exposure (mg TOS/kg body weight per day)InfantsToddlersChildrenAdolescentsAdultsThe elderly Age range 4–11 months12–35 months3–9 years10–17 years18–64 years≥ 65 years Min–max mean (number of surveys)0.006–0.181 (14)0.020–0.130 (17)0.015–0.143 (21)0.003–0.025 (23)0.002–0.019 (23)0.001–0.013 (25) Min–max 95th percentile (number of surveys)0.030–0.465 (13)0.072–0.344 (16)0.042–0.874 (21)0.009–0.090 (22)0.007–0.048 (23)0.004–0.046 (24)Abbreviation: TOS, total organic solids. Summary of the estimated dietary exposure to the food enzyme–TOS in six population groups. Abbreviation: TOS, total organic solids. Uncertainty analysis In accordance with the guidance provided in the EFSA opinion related to uncertainties in dietary exposure assessment (EFSA, 2006), the following sources of uncertainties have been considered and are summarised in Table 4. TABLE 4Qualitative evaluation of the influence of uncertainties on the dietary exposure estimate.Sources of uncertaintiesDirection of impact Model input data Consumption data: different methodologies/representativeness/underreporting/misreporting/no portion size standard+/−Use of data from food consumption surveys of a few days to estimate long‐term (chronic) exposure for high percentiles (95th percentile)+Possible national differences in categorisation and classification of food+/− Model assumptions and factors Selection of broad FoodEx categories for the exposure assessment+Exposure to food enzyme–TOS always calculated based on the recommended maximum use level+Use of recipe fractions to disaggregate FoodEx categories+/−Use of technical factors in the exposure model+/− Note: +, uncertainty with potential to cause overestimation of exposure; –, uncertainty with potential to cause underestimation of exposure. Qualitative evaluation of the influence of uncertainties on the dietary exposure estimate. Note: +, uncertainty with potential to cause overestimation of exposure; –, uncertainty with potential to cause underestimation of exposure. The conservative approach applied to estimate the dietary exposure to the food enzyme–TOS, in particular assumptions made on the occurrence and use levels of this specific food enzyme, is likely to have led to an overestimation of the exposure. Margin of exposure The comparison of the NOAEL (108 mg TOS/kg bw per day) from the 90‐day rat study with the mean exposure estimates of 0.001–0.181 mg TOS/kg bw per day and 0.004–0.874 mg TOS/kg bw per day at the 95th percentile resulted in margins of exposure (MoEs) for infants, toddlers, children, adolescents, adults and the elderly of at least 232, 314, 124, 1200, 2250 and 2348, respectively. CONCLUSIONS Based on the data provided and the derived MoEs, the Panel concluded that the food enzyme thermolysin produced with the non‐genetically modified A. caldiproteolyticus strain DP‐Fzj32 does not give rise to safety concerns under the intended conditions of use for infants, toddlers, adolescents, adults and the elderly. However, the MoE is insufficient to exclude safety concerns for children. DOCUMENTATION AS PROVIDED TO EFSA Technical dossier Application for authorisation of thermolysin from Geobacillus caldoproteolyticus (DP‐Fzj32). 26 February 2015. Submitted by Danisco US Inc. The dossier was updated on 8 February 2016. Additional information. 27 January 2026. Submitted by Danisco US Inc. Additional information. 13 April 2026. Submitted by Danisco US Inc. ABBREVIATIONS albumin antimicrobial resistance body weight Chemical Abstracts Service EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids EFSA Panel on Food Contact Materials, Enzymes and Processing Aids EFSA Panel on Food Enzymes EFSA Panel on Genetically Modified Organisms European Inventory of Existing Commercial Chemical Substances eosinophils Food and Agricultural Organization of the United Nations Food Enzyme Intake Model standardised food classification and description system Good Laboratory Practice genetically modified genetically modified organism International Union of Biochemistry and Molecular Biology Joint FAO/WHO Expert Committee on Food Additives potassium kiloDalton limit of detection lymphocytes mean corpuscular haemoglobin concentration margin of exposure no observed adverse effect level Organisation for Economic Co‐operation and Development prothrombin time raw material total organic solids total proteins whole genome sequence World Health Organization protease unit REQUESTOR European Commission QUESTION NUMBER EFSA‐Q‐2015‐00682 COPYRIGHT FOR NON‐EFSA CONTENT EFSA may include images or other content for which it does not hold copyright. In such cases, EFSA indicates the copyright holder and users should seek permission to reproduce the content from the original source. PANEL MEMBERS José Manuel Barat Baviera, Claudia Bolognesi, Francesco Catania, Gabriele Gadermaier, Ralf Greiner, Baltasar Mayo, Alicja Mortensen, Yrjö Henrik Roos, Marize de Lourdes Marzo Solano, Henk Van Loveren, Laurence Vernis and Holger Zorn. LEGAL NOTICE The full opinion will be published in accordance with Article 12 of Regulation (EC) No 1331/2008 once the decision on confidentiality will be received from the European Commission. Supporting information APPENDIX A Dietary exposure estimates to the food enzyme–TOS in details ACKNOWLEDGEMENTS The Panel wishes to thank the following for the support provided to this scientific output: Andrew Chesson, Lieve Herman. Dietary exposure estimates to the food enzyme–TOS in details Appendix A can be found in the online version of this output (in the ‘Supporting Information’ section). The file contains two sheets, corresponding to two tables. Table 1: Average and 95th percentile exposure to the food enzyme–TOS per age class, country and survey, obtained considering the actual consumers of the relevant food categories. Table 2: Contribution of food categories to the dietary exposure to the food enzyme–TOS per age class, country and survey. Population groups considered for the exposure assessment PopulationAge rangeCountries with food consumption surveys covering more than 1 day Infants From 16 weeks on up to and including 11 months of ageBulgaria, Croatia, Cyprus, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Poland, Portugal, Slovenia, Spain Toddlers From 12 months up to and including 35 months of ageBelgium, Bulgaria, Croatia, Cyprus, Denmark, Estonia, Finland, France, Germany, Hungary, Italy, Latvia, Montenegro*, the Netherlands, Poland, Portugal, Republic of North Macedonia*, Serbia*, Slovenia, Spain Children From 36 months up to and including 9 years of ageAustria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Italy, Latvia, Montenegro*, the Netherlands, Poland, Portugal, Republic of North Macedonia*, Serbia*, Spain, Sweden Adolescents From 10 years up to and including 17 years of ageAustria, Belgium, Bosnia and Herzegovina*, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Italy, Latvia, Montenegro*, the Netherlands, Poland, Portugal, Romania, Serbia*, Slovenia, Spain, Sweden Adults From 18 years up to and including 64 years of ageAustria, Belgium, Bosnia and Herzegovina*, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Montenegro*, the Netherlands, Poland, Portugal, Romania, Serbia*, Slovenia, Spain, Sweden The elderly a From 65 years of age and olderAustria, Belgium, Croatia, Cyprus, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Montenegro*, the Netherlands, Poland, Portugal, Romania, Serbia*, Slovenia, Spain, Sweden*Consumption data from these pre‐accession countries are not reported in Table 4 of this opinion; however, they are included in Appendix B for testing purpose. a The terms ‘children’ and ‘the elderly’ correspond, respectively, to ‘other children’ and the merge of ‘elderly’ and ‘very elderly’ in the Guidance of EFSA on the ‘Use of the EFSA Comprehensive European Food Consumption Database in Exposure Assessment’ (EFSA, 2011). Consumption data from these pre‐accession countries are not reported in Table 4 of this opinion; however, they are included in Appendix B for testing purpose. The terms ‘children’ and ‘the elderly’ correspond, respectively, to ‘other children’ and the merge of ‘elderly’ and ‘very elderly’ in the Guidance of EFSA on the ‘Use of the EFSA Comprehensive European Food Consumption Database in Exposure Assessment’ (EFSA, 2011). EFSA FEZ Panel (EFSA Panel on Food Enzymes) , Zorn, H. , Barat Baviera, J. M. , Bolognesi, C. , Catania, F. , Gadermaier, G. , Greiner, R. , Mayo, B. , Mortensen, A. , Roos, Y. H. , Solano, M. L. M. , Van Loveren, H. , Vernis, L. , Andreoli, C. , Terron, A. , Kovalkovičová, N. , Andryszkiewicz, M. , Cavanna, D. , Gomes, A. , & Liu, Y. (2026). Safety evaluation of the food enzyme thermolysin from the non‐genetically modified Anoxybacillus caldiproteolyticus strain DP‐Fzj32. EFSA Journal, 24(6), e10140. 10.2903/j.efsa.2026.10140 Adopted: 20 May 2026 Correspondence: Ask a Question The declarations of interest of all scientific experts active in EFSA's work are available at https://open.efsa.europa.eu/experts. Notes Regulation (EC) No 1332/2008 of the European Parliament and of the Council of 16 December 2008 on Food Enzymes and Amending Council Directive 83/417/EEC, Council Regulation (EC) No 1493/1999, Directive 2000/13/EC, Council Directive 2001/112/EC and Regulation (EC) No 258/97. OJ L 354, 31.12.2008, pp. 7–15. Regulation (EC) No 1331/2008 of the European Parliament and of the Council of 16 December 2008 establishing a common authorisation procedure for food additives, food enzymes and food flavourings. OJ L 354, 31.12.2008, pp. 1–6. Technical dossier/Additional information, 27 January 2026/Annex U. Technical dossier/Additional information, 27 January 2026/Annex W. Technical dossier/Additional information, 27 January 2026/Annex Y. Technical dossier/Additional information, 27 January 2026/Annex V. Technical dossier/Additional information, 27 January 2026/Annex X; Annex Z. Regulation (EC) No 852/2004 of the European Parliament and of the Council of 29 April 2004 on the hygiene of foodstuffs. OJ L 226, 25.6.2004, pp. 3–21. Technical dossier/p. 9, 42, 43, 49; Technical dossier/Annex J. Technical dossier/p. 43–51; Technical dossier/Annex K. Technical dossier/Additional information, 27 January 2026/Annex AB. Technical dossier/Annex G; Annex S. Technical dossier/Additional information, 13 April 2026/Annex 1. Technical dossier/p. 31–32; Technical dossier/Annex D. Technical dossier/p. 7, 35. Technical dossier/Annex C. Technical dossier/p. 8, 35–38; Technical dossier/Annex H. Technical dossier/p. 31, 63; Technical dossier/Annex B; Annex C; Annex F updated; Annex O; Annex R. Technical dossier/p. 8, 34, 72; Technical dossier/Annex E; Annex F updated; Technical dossier/Additional information, 27 January 2026/Annex AC; Annex AD. Technical dossier/Annex E; Annex F updated. Technical dossier/Annex O; Technical dossier/Additional information, 27 January 2026/Annex AC; Annex AD. LoDs: Pb = 5 mg/kg; Cd, Hg = 0.5 mg/kg each; As = 3 mg/kg. Technical dossier/p. 8, 34, 63; Technical dossier/Annex E; Annex F updated; Annex O; Technical dossier/Additional information, 27 January 2026/Annex AC. Technical dossier/p. 8, 34, 63; Technical dossier/Annex E; Annex F updated; Annex O; Technical dossier/Additional information, 27 January 2026/Annex AC. Technical dossier/Additional information, 13 April 2026/Annex 1. Technical dossier/Additional information, 27 January 2026/Annex AA. Technical dossier/p. 11, 16–17, 58–63; Technical dossier/Annex O; Annex P; Annex Q; Annex R. Technical dossier/Annex P; Technical dossier/Additional information, 27 January 2026/Annex 1. Technical dossier/Annex Q; Technical dossier/Additional information, 27 January 2026/Annex 1. Technical dossier/Annex R; Technical dossier/Additional information, 27 January 2026/Annex AE; Annex AF; Annex AG; Annex AH; Annex AI. Technical dossier/Annex R. Technical dossier/p. 12; Technical dossier/Annex S. Technical dossier/p. 64–65; Technical dossier/Annex S; Technical dossier/Additional information, 27 January 2026/Annex AJ. Technical dossier/Additional information, 27 January 2026. Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food information to consumers, amending Regulations (EC) No 1924/2006 and (EC) No 1925/2006 of the European Parliament and of the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 1999/10/EC, Directive 2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 2008/5/EC and Commission Regulation (EC) No 608/2004. Technical dossier/Additional information, 27 January 2026/p. 6; Technical dossier/Additional information, 13 April 2026/Annex 1/p. 2. Technical dossier/Additional information, 13 April 2026/Annex 1/p. 2. Technical dossier/p. 54. Technical dossier/p. 54. Version 1.1.1. REFERENCES Associated Data Supplementary Materials APPENDIX A Dietary exposure estimates to the food enzyme–TOS in details